Quickly Access Lean Library Popup
Skip to main content
medRxiv
  • Home
  • Submit
  • FAQ
  • Blog
  • ALERTS / RSS
  • About
Advanced Search

Understanding the pathways leading to socioeconomic inequalities in HIV testing uptake in 18 sub-Saharan African countries: a mediation analysis

View ORCID ProfilePearl Anne Ante-Testard, View ORCID ProfileMohamed Hamidouche, View ORCID ProfileBénédicte Apouey, View ORCID ProfileRachel Baggaley, View ORCID ProfileJoseph Larmarange, View ORCID ProfileTarik Benmarhnia, View ORCID ProfileLaura Temime, View ORCID ProfileKévin Jean
doi: https://doi.org/10.1101/2021.09.18.21263768
This article is a preprint and has not been peer-reviewed [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.
00000040 Comments0 TRiP Peer Reviews0 Community Reviews0 Automated Evaluations0 Blog/Media Links0 Videos4 Tweets
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF

Abstract

Introduction Although socioeconomic inequalities in HIV prevention, testing and treatment services have been well documented, their drivers remain poorly understood. Understanding the different pathways between socioeconomic position and HIV testing across different countries could help designing tailored programs aimed at reducing such inequalities.

Methods We analysed data from Demographic and Health Surveys conducted between 2010 and 2018 in 18 sub-Saharan African countries (Burkina Faso, Cameroon, Côte d’Ivoire, Congo DR, Ethiopia, Guinea, Kenya, Lesotho, Liberia, Malawi, Mali, Niger, Rwanda, Senegal, Sierra Leone, Tanzania, Zambia and Zimbabwe). Using a potential outcomes framework and the product method, we decomposed the total effect linking wealth and recent (< 12 months) HIV testing into i) direct effects, and ii) indirect effects, via demand-related (related to individual’s ability to perceive need for care and inclination to seek care) or supply-related (related to individual’s ability to reach, pay for and engage in health care) mediators. Multivariable gender-specific modified Poisson models were fitted to estimate proportions mediated, while accounting for exposure-mediator interaction when present.

Results A total of 392,044 participants were included in the analysis. Pro-rich wealth-related inequalities were observed in a majority of countries, with nine countries with high levels of inequalities among women and 15 countries among men.

The indirect effects of each mediator varied greatly across countries. The proportion mediated tended to be higher for demand-related than for supply-related mediators. For instance, among women, HIV-related knowledge was estimated to mediate up to 12.1% of inequalities in Côte d’Ivoire; this proportion was up to 31.5% for positive attitudes toward people living with HIV (PLHIV) in Senegal. For the four supply-related mediators, the proportion mediated was systematically below 7%. Similar conclusions were found when repeating analyses on men for the demand-related mediators, with higher proportions mediated by positive attitudes toward PLHIV (up to 39.9% in Senegal).

Conclusions Our findings suggest that socioeconomic inequalities in HIV testing may be mediated by the demand-side more than supply-side characteristics, with important variability across countries. Overall, the important inter-country heterogeneity in pathways of socioeconomic inequalities in HIV testing illustrates that addressing inequalities requires tailored efforts as well as upstream interventions.

A French version of the abstract is available upon request from the corresponding author.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study was funded by INSERM-ANRS (France Recherche Nord and Sud Sida-HIV Hepatites), grant number ANRS 12377-B104. Disclaimer: Funding agency had no role in the study design, data collection and analysis.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The national implementing agencies or research institutes that conducted the surveys were responsible for ethical clearance which assured informed consent from the participants prior to their involvement and guaranteed confidentiality of information.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted October 22, 2021.
Download PDF
Print/Save Options

Author Declarations

Supplementary Material

Data/Code
Email
Share
Citation Tools
COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

Subject Area

  • HIV/AIDS
Subject Areas
All Articles
  • Addiction Medicine (175)
  • Allergy and Immunology (423)
  • Anesthesia (97)
  • Cardiovascular Medicine (902)
  • Dentistry and Oral Medicine (172)
  • Dermatology (102)
  • Emergency Medicine (257)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (408)
  • Epidemiology (8810)
  • Forensic Medicine (4)
  • Gastroenterology (405)
  • Genetic and Genomic Medicine (1871)
  • Geriatric Medicine (179)
  • Health Economics (389)
  • Health Informatics (1294)
  • Health Policy (644)
  • Health Systems and Quality Improvement (495)
  • Hematology (207)
  • HIV/AIDS (397)
  • Infectious Diseases (except HIV/AIDS) (10593)
  • Intensive Care and Critical Care Medicine (565)
  • Medical Education (193)
  • Medical Ethics (52)
  • Nephrology (218)
  • Neurology (1770)
  • Nursing (105)
  • Nutrition (267)
  • Obstetrics and Gynecology (344)
  • Occupational and Environmental Health (461)
  • Oncology (968)
  • Ophthalmology (285)
  • Orthopedics (107)
  • Otolaryngology (177)
  • Pain Medicine (118)
  • Palliative Medicine (43)
  • Pathology (265)
  • Pediatrics (560)
  • Pharmacology and Therapeutics (266)
  • Primary Care Research (221)
  • Psychiatry and Clinical Psychology (1847)
  • Public and Global Health (3998)
  • Radiology and Imaging (657)
  • Rehabilitation Medicine and Physical Therapy (344)
  • Respiratory Medicine (538)
  • Rheumatology (216)
  • Sexual and Reproductive Health (178)
  • Sports Medicine (167)
  • Surgery (199)
  • Toxicology (37)
  • Transplantation (107)
  • Urology (80)

Evaluation/discussion of this paper   x